A Call for Consensus in Defining Efficacy in Clinical Trials for Opioid Addiction: Combined Results from a Systematic Review and Qualitative Study in Patients Receiving Pharmacological Assisted Therapy for Opioid Use Disorder

Abstract

Background Given the complex nature of opioid addiction treatment and the rising number of available opioid substitution and antagonist therapies (OSAT), there is no ‘gold standard’ measure of treatment effectiveness, and each successive trial measures a different set of outcomes which reflect success in arbitrary or opportune terms.We sought to describe the variation in current outcomes employed across clinical trials for opioid addiction, as well as determine whether a discrepancy exists between the treatment targets that patients consider important and how treatment effectiveness is measured in the literature. Methods We searched nine commonly used databases (e.g. EMBASE, MEDLINE) from inception to August 1, 2015. Outcomes used across trials were extracted and categorized according to previously established domains. To evaluate patient reported goals of treatment, semi-structured interviews were conducted with 18 adults undergoing methadone treatment. Results We identified 60 trials eligible for inclusion. Once outcomes were categorized into eight broad domains (e.g. abstinence/substance abuse), we identified 21 specific outcomes with furthermore 53 subdomains and 118 measurements. Continued opioid use and treatment retention were the most commonly reported measures (46%, n=28). The majority of patients agreed that abstinence from opioids was a primary goal in their treatment, however they also stressed goals under-reported in clinical trials. Conclusion There is inconsistency in the measures used to evaluate the effectiveness of OSATs. Individual and population level decision making is being guided by a standard of effect considered useful to researchers yet in direct conflict with what patients deem important. PROSPERO ID CRD42013006507

Role of microRNAs in the pathophysiology of addiction

“…Presently, several pre‐clinical studies are being performed using miRNAs as biomarkers or therapeutics for diseases, but no clinical trials, and few pre‐clinical trials, exist specifically for addiction (Creed, 2018; Dennis et al, 2020; Edemann‐Callesen, Barak, Hadar, & Winter, 2020; Whyte, Torregrossa, Barker, & Gourley, 2018). Many drug abuse studies rely on self‐reported data, and reliable diagnostics are difficult and expensive (Nora D. Volkow, Koob, & Baler, 2015).…”

Investigating and addressing the immediate and long-term consequences of the COVID-19 pandemic on patients with substance use disorders: a scoping review and evidence map protocol

“…Outcomes will be coded as being patient important or not, as what was previously defined among a substance use population. 27 For the purpose of evidence mapping, data will be grouped according to outcome, prognostic factors and whether outcomes selected were patient-important.…”